![Pharmacogenetic-guided glimepiride therapy in type-2 diabetes mellitus: a cost-effectiveness study | The Pharmacogenomics Journal Pharmacogenetic-guided glimepiride therapy in type-2 diabetes mellitus: a cost-effectiveness study | The Pharmacogenomics Journal](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41397-021-00232-w/MediaObjects/41397_2021_232_Fig1_HTML.png)
Pharmacogenetic-guided glimepiride therapy in type-2 diabetes mellitus: a cost-effectiveness study | The Pharmacogenomics Journal
![Open Medic : bases complémentaires sur les dépenses de médicaments - 2014 à 2021 | L'Assurance Maladie Open Medic : bases complémentaires sur les dépenses de médicaments - 2014 à 2021 | L'Assurance Maladie](https://assurance-maladie.ameli.fr/sites/default/files/styles/webp_ckeditor/public/thumbnails/image/open_medic_2.png.webp?itok=OVAKtPGv)
Open Medic : bases complémentaires sur les dépenses de médicaments - 2014 à 2021 | L'Assurance Maladie
Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France | PLOS ONE
![Antibiotics | Free Full-Text | Outpatient Antibiotic Prescriptions in France: Patients and Providers Characteristics and Impact of the COVID-19 Pandemic Antibiotics | Free Full-Text | Outpatient Antibiotic Prescriptions in France: Patients and Providers Characteristics and Impact of the COVID-19 Pandemic](https://pub.mdpi-res.com/antibiotics/antibiotics-11-00643/article_deploy/html/images/antibiotics-11-00643-g001-550.jpg?1652318771)